Biotech | December 22, 2021
Piramal Pharma takes a minority stake in Yapan Bio
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Since its launch, the medical devices park in Sultanpur has received overwhelming response with more than 50 companies lining up to set up their manufacturing or research and development units
The company is focused on the development of novel treatments for RNA viruses
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
The fund aims at investing in companies that extends human healthspan
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Subscribe To Our Newsletter & Stay Updated
